NP896282.RAqPu9SvOmBz eUjY7ae OJCtFeDQegTtstfE-CHNmQYQ
has assertion: NP896282.RAqPu9SvOmBz eUjY7ae OJCtFeDQegTtstfE-CHNmQYQ130 assertion
has provenance: NP896282.RAqPu9SvOmBz eUjY7ae OJCtFeDQegTtstfE-CHNmQYQ130 provenance
has publication info: NP896282.RAqPu9SvOmBz eUjY7ae OJCtFeDQegTtstfE-CHNmQYQ130 publicationInfo
type: Nanopublication
created: 2016-05-13T12:48:30+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP896282.RAqPu9SvOmBz eUjY7ae OJCtFeDQegTtstfE-CHNmQYQ130 assertion
type: Assertion
description: [Skin disorders are among the most common adverse events related to treatment with epidermal growth factor receptor (EGFR) kinase inhibitors, and of these, erlotinib is known to cause more frequent and severe skin disease than other agents in this class.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/21606217
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0